UNSPSC 51321502: Probucol

This classification denotes an anti-lipidemic agent with the molecular formula C31H48O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3CTH044XJ, chemically known as 4,4-(isopropylidenedithio)bis(2,6-di-tert-butylphenol) but generally known as probucol, which bears US NIH Compound Identifier 4912. European Medicines Agency schedules Probucol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10054MIG.

UNSPSC 51321502 Probucol is a Commodity code that captures state and local procurement of advanced life support and emergency medications supplied to fire rescue services, health systems, and pharmacy benefit programs. State and local governments buy specific pharmaceutical products under this code — labetalol, epinephrine, adenosine, diltiazem, and other injectable or oral medications — sourced through direct manufacturer contracts, authorized wholesaler networks, or cooperative purchasing alliances. Issuing bodies include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing consortia. The Tampa Fire Rescue procurement and the Texas HHS pharmacy initiative represent the kinds of end-user demand and state-level strategic sourcing that drive activity under the code.

Recent opportunities span Florida, Texas, and a multistate footprint anchored in Minnesota and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026 for Advanced Life Support Medications with a due date of April 8, 2026 and an estimated contract value of $40,000, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount not to exceed $10,000; the contract runs one year from award with two optional one-year renewals and up to three additional 30-day unilateral extensions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with award effective July 1, 2026 and a two-year contract term. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 as preliminary market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor capabilities for direct contracting with self-insured employer health plans outside traditional PBM, GPO, and wholesaler arrangements.